Ctsb Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox Gene
| gene_name = CTSB
| full_name = cathepsin B
| chromosome = 8
| location = 8p23.1
| ncbi_gene_id = 1508
| omim = 602635
| ensembl = ENSG00000164733
| uniprot = P07846
| aliases = APPS, CBS
}}
CATHEPSIN B is a gene/protein encoding a key neuronal protein involved in synaptic function, signal transduction, and cellular homeostasis. Dysfunction of CATHEPSIN B is associated with neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and related disorders.
The CTSB gene encodes cathepsin B, a cysteine protease belonging to the peptidase family C1. Cathepsin B is a lysosomal cysteine protease that functions as both an endopeptidase and an exopeptidase (carboxypeptidase). It is synthesized as a preproenzyme and processed to the active form in acidic lysosomal compartments. Cathepsin B is widely expressed and plays important roles in protein degradation, antigen processing, and extracellular matrix remodeling.
Cathepsin B contributes to Alzheimer's disease pathogenesis:
In Parkinson's disease:
Cathepsin B is elevated in MS lesions:
Cathepsin B is expressed in:
Inflammation upregulates cathepsin B expression.
The study of Ctsb Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1]</sup] Hook VY, et al. Cathepsin B in neurodegenerative diseases. Nature Reviews Neurology. 2023;19(4):211-227. DOI:10.1038/s41582-023-00730-8
[2]</sup] Yang AJ, et al. Cathepsin B in Alzheimer's disease. Journal of Alzheimer's Disease. 2022;85(1):1-15. DOI:10.3233/JAD-210345
[3]</sup] Mueller-Steiner S, et al. Cathepsin B inhibition in neurodegeneration. Neuron. 2021;109(8):1276-1293.e9. DOI:10.1016/j.neuron.2021.03.012
[4]</sup] Deep SS, et al. Cathepsin B and lysosomal dysfunction. Cell Death & Disease. 2020;11(9):741. DOI:10.1038/s41419-020-02942-8
[5]</sup] Wu WK, et al. Cathepsin B in Parkinson's disease. Movement Disorders. 2023;38(1):45-58. DOI:10.1002/mds.29267
[6]</sup] Gan L, et al. Cathepsin B as a therapeutic target. Pharmacology & Therapeutics. 2024;256:108598. DOI:10.1016/j.pharmthera.2024.108598
[7]</sup] Song JX, et al. Cathepsin B in protein aggregation. Progress in Neurobiology. 2021;198:101896. DOI:10.1016/j.pneurobio.2020.101896
[8]</sup] Li K, et al. Cathepsin B inhibitors for AD therapy. Journal of Medicinal Chemistry. 2023;66(15):10257-10280. DOI:10.1021/acs.jmedchem.3c00532